Evidence map›Paper›PMID 41304808›Full record

ArticlePharmaceutics2025

Engineered Fenretinide- and Tocilizumab-Releasing Janus Nanoparticles for Site-Directed Immunochemoprevention of Squamous Cell Carcinoma of the Lung.

Daren Wang, Albert Chang, Fortune Shea, Yifei He, Richard Spinney, Jonathan D Whitsett, Joerg Lahann, Susan R Mallery

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daren WangDivision of Oral & Maxillofacial Pathology, College of Dentistry, The Ohio State University, 305 W 12th Ave., Columbus, OH 43210, USA.ORCID 0000-0002-5621-6295
Albert ChangBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48105, USA.ORCID 0000-0002-6792-3059
Fortune SheaDivision of Oral & Maxillofacial Pathology, College of Dentistry, The Ohio State University, 305 W 12th Ave., Columbus, OH 43210, USA.
Yifei HeBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48105, USA.ORCID 0000-0001-8354-8263
Richard SpinneyDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-8074-3386
Jonathan D WhitsettDivision of Oral & Maxillofacial Pathology, College of Dentistry, The Ohio State University, 305 W 12th Ave., Columbus, OH 43210, USA.
Joerg LahannBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48105, USA.
Susan R MalleryDivision of Oral & Maxillofacial Pathology, College of Dentistry, The Ohio State University, 305 W 12th Ave., Columbus, OH 43210, USA.ORCID 0000-0002-8989-6629

Funding

Formulation, Evaluation, and Phase 0 Trial of Nanoparticle Releasing Oral Thin Film for OSCC ChemopreventionR01CA258757 · NCI · OHIO STATE UNIVERSITY · PI Susan R Mallery · 2022 to 2026
$3.0M
National Institutes of Health Grant R01CA258757NCI NIH HHS R01 CA258757
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

fenretinideJanus nanoparticleslung cancer

Identifiers

PMID41304808
PMCPMC12655460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.